Scotland approves breast cancer drug deemed 'too expensive' for England
Kadcyla to be offered north of the border, while NHS Scotland also commits to funding 'costly' PrEP HIV drug

A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
Scotland's health service has approved a breast cancer drug that is being withdrawn in England for being too expensive.
Kadcyla has been shown to extend the lives of patients dying from an aggressive form of breast cancer by an average of nine months.
The Scottish Medicines Consortium (SMC) said the drug would allow patients "more time with their families and in some cases return to work".
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
However, last year the National Institute for Health and Care Excellence (Nice), which decides which drugs and treatments are available on the NHS, said Kadcyla was too expensive.
More than 13,000 women have signed a petition calling for the drug to be made routinely available. A decision on whether to approve its availability will be made this summer, said Nice.
NHS Scotland has also become the first health service in the UK to fund the use of a drug that reduces the risk of HIV infection by 90 per cent. Pre-exposure prophylaxis (PrEP) will be free to those who need it within weeks.
The SMC's ruling follows "a fierce legal battle south of the border last year", says the Daily Telegraph, when NHS England unsuccessfully argued it was not responsible for providing the medicine.
Health officials south of the border have resisted approving PrEP due to its cost, "although it is a lot cheaper than a lifetime of HIV treatment which could cost £360,000", The Guardian reports.
PrEP has not yet been approved for routine preventative use, although following the fight last year, NHS England said it would make the drug available through a trial involving at least 10,000 people over the next three years.
Aids campaigners believe the SMC decision will put pressure on England's health service to change the way it deals with preventative HIV measures.
Deborah Gold, chief executive of the National Aids Trust, said: "This game-changing prevention tool has the potential to massively reduce HIV rates and turn Scotland into a model internationally of how to do HIV prevention well.
"The speed and decisiveness of the Scottish process contrasts starkly with delays in the other three UK nations."
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
-
Should you fire your financial adviser? 4 signs it's time to say goodbye.
The Explainer Breakups are never fun, but you have to protect your wallet
By Becca Stanek Published
-
The daily gossip: Man arrested in connection with shooting of Tupac Shakur, an OceanGate movie is in the works, and more
Feature The daily gossip: September 29, 2023
By Brendan Morrow Published
-
What to expect from an El Niño winter
The Explainer Things might be different thanks to this well-known weather phenomenon
By Devika Rao Published
-
Good health news: seven surprising medical discoveries made in 2023
In Depth A fingerprint test for cancer, a menopause patch and the shocking impacts of body odour are just a few of the developments made this year
By The Week Staff Published
-
Neanderthal gene ‘caused up to a million Covid deaths’
Speed Read Genetic tweak found in one in six Britons means cells in the lungs are slower to launch defences
By The Week Staff Published
-
Where did Omicron come from?
Today's Big Question Some experts believe the variant may have hidden and evolved in an immunosuppressed patient’s body
By Chas Newkey-Burden Published
-
Legalising assisted dying: a complex, fraught and ‘necessary’ debate
Speed Read The Assisted Dying Bill – which would allow doctors to assist in the deaths of terminally ill patients – has relevance for ‘millions’
By The Week Staff Last updated
-
Vaccinating children: it’s decision time for the health secretary as kids return to school
Speed Read Sajid Javid readying NHS England to roll out jab for children over 12, amid fears infections will rocket
By The Week Staff Last updated
-
‘Vaccination blunts, but does not defeat’: exploring Israel’s fourth Covid wave
Speed Read Two months ago, face masks were consigned to bins. Now the country is in a ‘unique moment of epidemiological doubt’
By The Week Staff Published
-
Thousands told to self-isolate in Covid app pinging error, claims Whitehall whistleblower
Speed Read Source says Matt Hancock was privately told of the issue shortly before he resigned as health secretary
By The Week Staff Published
-
Record 5.45m people on NHS England waiting lists
Speed Read Health chief warns that crisis is nearing ‘boiling point’ as backlog grows
By The Week Staff Last updated